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Background: Intermittent claudication resulting from peripheral arterial disease (PAD) can substantially impair walking
function. The Walking Impairment Questionnaire (WIQ) assesses patient self-reported difficulty in walking. Currently
this questionnaire is validated for interviewer administration only. Since this can be burdensome in a large clinical trial,
we examined the effects of alternative methods of administration on patient responses on the WIQ.
Methods: The WIQ, which consists of four subscales (pain severity, distance, speed, stairs), was modified to be
self-administered or interviewer-administered by telephone. Patients with PAD were recruited from two sites and
randomized into two groups: in group 1 the WIQ was self-administered, then telephone-administered; in group 2 the
WIQ was telephone-administered, then self-administered. The two administrations occurred 4 to 7 days apart.
Additional measures (SF-36, EQ-5D, and PAD symptom scale) and clinical data were included to further assess the
validity of the WIQ and symptoms in patients with claudication. Telephone interviews were conducted by trained
interviewers using standardized scripts. Two-week test-retest reliability was assessed for both the self-administered WIQ
(group 1) and the telephone-administered WIQ (group 2).
Results: Sixty patients were recruited at two sites (n  30 per group). Seventy-eight percent were men; mean patient age
was 67.1 years; and 83% of patients were white. Mean duration of PAD symptoms was 6.8 years. No significant
differences were observed in WIQ subscale scores between self administration and telephone administration. No
interaction effects between order and method of administration were detected. Cronbach  for distance, speed, and
stair-climbing subscales ranged from 0.82 to 0.94. Correlations among WIQ subscales and the symptom scale were good
(r  0.34 to 0.57). Correlations of WIQ subscales with physical health subscales of the SF-36 (r  0.24-0.59) were
higher than for mental health–related subscales (r  0.08-0.26).
Conclusions: The modified WIQ demonstrated good reliability and validity with both methods of administration. These
results suggest that the self-administered and telephone-administered versions of the WIQ can be used reliably and
efficiently in clinical trials. (J Vasc Surg 2003;38:296-304.)
Peripheral arterial disease (PAD) may or may not be
associated with symptomatic intermittent claudication. The
overall prevalence of intermittent claudication is 4.5% in
men and women between age 55 years and 74 years, and
incidence increases to greater than 7% in persons older than
75 years.1 People with intermittent claudication and PAD
often have impaired walking ability because of pain while
walking, and PAD adversely affects levels of physical activ-
ity, mobility, and overall health-related quality of life
(HRQL).2-4 Thus clinical trials that evaluate the effective-
ness of treatments for PAD would benefit from a reliable
and valid questionnaire that assesses walking impairment.
The Walking Impairment Questionnaire (WIQ), cre-
ated by researchers at the University of Colorado Health
Sciences Center, was developed to characterize the degree
of walking impairment in patients with PAD and as a
measure of efficacy for interventions to reduce symptoms in
patients with PAD.5 This measure is reliable and valid4,5
and has been effectively used in a number of studies as an
interviewer-administered questionnaire.3,6,7 However, in-
terviewer administration of questionnaires is often imprac-
tical in a clinical trial setting, because of cost and interviewer
burden. The WIQ was modified to a self-administered
format by MEDTAP International, a private health out-
comes research firm, to facilitate patient administration of
the WIQ in large multicenter international clinical trials
(Figure). In addition, although the WIQ has been admin-
istered via telephone interview in clinical trials with good
correlation with treadmill testing and demonstrated re-
sponsiveness,8 it has not been formally validated. As
method of administration can affect participant responses
and the resulting reliability and validity of an instru-
ment,9-11 validation of the questionnaire in the modified
form is required before its use in an investigational or
clinical setting. The purpose of this study was to validate the
self-administered and telephone-administered versions of
the WIQ.
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METHODS
Questionnaire modification
The WIQ evaluates patient-reported walking speed,
distance, stair climbing ability, and limitations in walking
ability. To facilitate self-administration and telephone ad-
ministration, the WIQ was slightly modified:
1. The differential diagnosis section was deleted. This sec-
tion examined possible causes of walking impairment
other than claudication, eg, cardiovascular, pulmonary,
and musculoskeletal disease.
2. A single pain scale item was separated into two symp-
tom areas, ie, calves and buttocks, to differentiate
symptoms.
3. Instructions for self-administration were added.
4. The response option, “Don’t do for other reasons,” was
added.
The modifiedWIQ has 16 questions in four categories:
pain (2 questions); walking distance (7 questions); walking
speed (4 questions); and stair climbing (3 questions). Cog-
nitive debriefing interviews with the modified WIQ con-
ducted before this validation study in patients with PAD
(Continued.) Walking Impairment Questionnaire.
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indicated that the language and format were acceptable to
patients. For this study, three versions of the WIQ were
administered: telephone-administered WIQ, telephone-
administered modified WIQ, and self-administered modi-
fied WIQ.
Participants
Participants who met inclusion or exclusion criteria
were recruited from two cardiology clinics, the University
of ColoradoHealth Sciences Center and EmoryUniversity.
Patients were included if they were older than 40 years, and
had PAD, with ankle-brachial systolic blood pressure ratio
(ABI) 0.90 or less at rest. Patients were excluded if they had
cognitive impairments; walking limitations due to other
health conditions, eg, chronic obstructive pulmonary dis-
ease, heart disease, neuromuscular disorder, arthritis, or
angina; severe psychiatric disorders; a serious life event in
the previous 3 months that may have affected HRQL; or
were scheduled to undergo an interventional procedure,
eg, bypass surgery or angioplasty, within the next 4 weeks.
In an effort to obtain a distribution of disease severity,
approximately half of the patient sample was recruited on
the basis of ABI less than 0.60 at rest.
Measures
Clinical characteristics were obtained from patient
medical charts, and included ABI, duration of illness, pre-
vious interventions or surgeries, concomitant medications,
and comorbid conditions, eg, angina, arthritis, cancer, and
diabetes.
SF-36 Health Survey. This 36-item generic health
status measure12 assesses eight domains: physical function,
bodily pain, vitality, mental health, role limitations due to
physical problems, general health perceptions, social func-
tioning, and role limitations due to emotional problems.
The subscale scores have adequate reliability and validity,12
and the SF-36 is responsive to interventions and improve-
ments in PAD symptoms, particularly the physical function
subscale.4,7,13-15
EQ-5D. The EQ-5D16 is a preference-basedmeasure-
ment that produces a single index score on a continuum
ranging from perfect health (1) to death (0). This health
index score represents the patient’s subjective health status,
and incorporates a preference value for this overall health
state. The score is comprised of five dimensions: mobility,
usual activity, anxiety or depression, self-care, and pain or
discomfort. Scoring the EQ-5D requires conversion of
reported health-related domains into one of 243 possible
health states. These health states can then be converted to a
weighted health index based on general population data. In
previous studies of PAD, the EQ-5D effectively discrimi-
nated between patients with different symptom severity and
reflected patient improvement after revascularization
procedures.2,13,14
Overall Treatment Effect Scale. The Overall Treat-
ment Effect Scale scale17 has been used in several clinical
studies.18,19 The initial question asks whether PAD symp-
toms have improved, remained the same, or worsened since
the last evaluation. Participants who indicate that symp-
toms have improved or worsened are asked to rate the
degree of improvement on a 7-point scale, from 1 (almost
the same, hardly better at all) to 7 (a very great deal better)
and1 (almost the same, hardly worse at all) to7 (a very
great deal worse). A score between 1 and 1 was consid-
ered to indicate no change in PAD symptoms, or “stable”
disease.19 With the Overall Treatment Effect Scale, PAD
symptoms were classified as improving, stable, or worsen-
ing for the test-retest analyses.
PAD Symptom Scale. The PAD Symptom Scale, de-
veloped by Gibbons et al,20 contains eight PAD symptoms:
cramping in the calf, cramping in the buttock, leg swelling,
sores or ulcers, limping, resting toe or foot pain, walking
toe or foot pain, and nighttime leg pain. Each item is rated
on a 6-point Likert scale, ranging from 1 (none of the time)
to 6 (all of the time). No psychometric data have been
reported for this instrument, we evaluated the psychomet-
ric properties of this instrument.
Procedures
MEDTAP International coordinated and managed the
study. Each site received institutional review board ap-
proval before trial initiation. Subjects provided written
consent at the time of the first self-administered WIQ.
Verbal consent was obtained if the patient was initially
recruited by telephone and randomized to telephone ad-
ministration first. Patients were reimbursed for their time
and expenses associated with study participation.
Eligible subjects were identified from medical chart
screening and were randomly assigned to one of two
groups based on sequence of WIQ administration (Table
I). Group 1 participants completed the WIQ as follows:
self-administered modified WIQ at baseline, telephone-
administered original WIQ at day 4 to 7, and self-adminis-
tered modified WIQ at week 2. Group 2 participants com-
pleted theWIQ as follows: telephone-administered original
WIQ at baseline, self-administered modified WIQ at day 4
Table I. Sequence of WIQ administration by study group
Study group
Baseline Day 4-7 Week 2 Week 4
Administration WIQ Administration WIQ Administration WIQ Administration WIQ
Group 1 (n  30) Self Modified Telephone Original Self Modified — —
Group 2 (n  30) Telephone Original Self Modified Telephone Modified Telephone Modified
WIQ, Walking Impairment Questionnaire.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 2 Coyne et al 299
to 7, telephone-administered modifiedWIQ at week 2, and
telephone-administered modified WIQ again at week 4.
Self-administered questionnaires were completed in a
private room at the clinic. Telephone interviews were con-
ducted by trained clinical research coordinators. At the
time of baseline self-administration, patients also com-
pleted a clinical information form and all other outcome
measures. For all follow-up visits, the Overall Treatment
Effect Scale was administered first, to determine whether
patients experienced changes in health status between as-
sessments. The week 2 and week 4 visits were to occur at 14
 3 days and 28  3 days after the baseline evaluation.
Data analysis
Descriptive statistics were used to characterize the sam-
ple. The X2 test was used to evaluate categorical data; t tests
were used to evaluate continuous data. These analyses
evaluated the reliability, reproducibility, and validity of the
WIQ subscale scores across methods of administration.
Internal consistency reliability was assessed using Cron-
bach’s , which was compared across methods of adminis-
tration with the Feldt approach for related samples.21 Re-
producibility across methods (score stability) was assessed
with intraclass correlation coefficients (ICC), Pearson cor-
relation coefficients, and paired t tests for baseline and day
4 to 7 data from both groups. Test-retest reliability was
evaluated with ICC, Pearson correlations, and paired t tests
for the self-administered WIQ by using group 1 data at
baseline and week 2 and for the telephone-administered
WIQ by using group 2 data at week 2 and week 4. Con-
struct validity was assessed by examining the magnitude
and direction of the relationship between the modified
WIQ and SF-36, EQ-5D, and PAD Symptom Scale. Study
subjects were categorized into groups according to disease
severity on the basis of ABI score (0.6 vs0.6 and0.9),
and data were compared with t tests and X2 test, as appro-
priate. If data were missing, the patient was excluded from
the specific analysis.
Scoring of theWIQ is by subscale, and involves weight-
ing each response, summing the weighted responses, and
dividing by the total possible weighted score to obtain a
percent score. Each subscale has a range of 0% to 100%,
with lower scores indicating greater impairment on the
subscale. For the original WIQ, when responses were miss-
ing within a subscale (which was rare because of interviewer
administration), the subscale was coded as missing. For the
modified WIQ, the response option “Don’t do for other
reasons” was added to lessen the number of missing re-
sponses without penalizing the patient score because of not
doing activities for reasons other than walking impairment.
If fewer than 50% of the subscale items were coded as
“Don’t do for other reasons,” the weighted item was
removed from the denominator of the weighted score, to
calculate a percent score based on the items that were
applicable to the participant. If more than 50% of the
subscale items were coded as “Don’t do for other reasons,”
the subscale was coded as missing.
RESULTS
Sixty patients were recruited from the two clinical cen-
ters and randomized to two groups of 30 patients each.
Demographic and clinical characteristics were similar be-
tween groups (Table II, online only). Most participants
were men (78%); patient mean age was 67.1 years; 28% of
patients continued to work either full-time or part-time,
and 55% were retired. In 45% of patients ABI was 0.60 or
less; 85% of patients were either current or previous smok-
ers; and 78% of patients had a history of hypertension.
Baseline scores for all outcome measures were as expected
for this sample with PAD and comorbid conditions. There
were no differences between groups in any health outcome
measures according to disease severity compared by ABI
(Table III). This remained true when comparing disease
severity at lower ABI cutoff points ( 0.5 vs  0.5), with
the exception of the bodily pain subscale on the SF-36,
where the group with ABI less than 0.5 reported signifi-
Table III. Comparison of outcomes by disease severity
ABI  0.6 (N  27) Mean  SD 0.6  ABI  0.9 (N  33) Mean  SD P
WIQ, Modified
Pain 52.9  22.4 (n26) 63.3  20.7 .07
Distance 26.0  20.9 (n24) 25.6  19.8 (n30) .94
Speed 34.2  26.1 (n23) 32.1  19.0 (n29) .74
Stair-climbing 48.1  21.5 (n22) 46.7  26.7 (n24) .84
SF-36 Health Survey
Physical functioning 40.2  16.1 42.5  15.9 (n32) .58
Role physical 32.4  39.1 43.2  40.6 .30
Bodily pain 55.8  24.6 50.1  19.6 .33
General health 53.9  17.3 57.6  20.2 .45
Vitality 51.7  24.0 45.3  22.5 .29
Social functioning 78.2  22.6 76.9  22.8 .82
Role emotional 74.1  42.7 74.7  37.3 .95
Mental health 76.0  18.4 74.1  16.0 .67
EQ-5D 0.66  0.18 0.61  0.23 .36
VAS 66.4  19.1 (n26) 65.9  15.5 .90
PAD Symptom Scale 19.5  7.2 18.2  6.5 .47
WIQ, Walking Impairment Questionnaire; ABI, ankle-brachial index; VAS, visual analog scale; PAD, peripheral arterial disease.
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cantly lower scores (P  .03). Bodily pain was also the
subscale in which ABI was most highly correlated (r 
0.24; P  .06).
Mean time between initial and second administration
of the WIQ was 6.2 days (range, 4 to 12 days). The
distance, speed, and climbing stairs subscales of the modi-
fied WIQ demonstrated good internal consistency (
0.80), regardless of method of administration (Table IV).
The internal consistency of the self-administered modified
WIQ was significantly higher than the original WIQ based
on the Feldt statistic. The Cronbach  for the telephone-
administered and self-administeredmodifiedWIQwas sim-
ilar except in the stair-climbing subscale, with telephone
administration significantly lower than self- administration
(P  .01). No differences in internal consistency reliability
were noted among subscales when comparing the original
and modified telephone administration. The pain subscale
of the modified WIQ did not demonstrate adequate inter-
nal consistency; however, this two-item subscale was not
expected to perform well, because the items evaluate differ-
ent pain locations (buttocks vs calves). The original pain
subscale is a single item; therefore its internal consistency
could not be evaluated.
No interaction effects between order of administration
(self-administered first vs telephone-administered first) and
method of administration were noted. The distance and
speed subscale scores were not statistically different across
methods of administration (Table V). Pain scores were
significantly different; however, this was attributed to the
difference in the number of items within the subscale
between the originalWIQ and themodifiedWIQ. The stair
climbing subscale scores of the original versus the modified
WIQ were also significantly different.
The mean change in scores from time 1 to time 2 varied
from 0.3 to 4.8 on a 100-point scale (Table VI). Pearson
product moment correlations were moderate to high, and
significant (P  .0001) for all subscales except the pain
subscale. ICC was moderate to high (0.58) for each
subscale except the pain subscale. Test-retest reliability was
high for both the self-administered and telephone-admin-
istered modified WIQ, with ICC ranging between 0.68
(pain, self-administered WIQ) and 0.88 (stair-climbing,
telephone-administered WIQ) (Table VII).
Correlation of WIQ subscales with physical health–
related subscales on the SF-36 (r 0.24-0.59) were higher
than mental health–related subscales (r  0.08-0.26).
Table IV. Internal consistency by WIQ version and method of administration
WIQ subscales
Cronbach 
Feldt statistic* P value
(original vs modified)
Telephone
(original)
Self
(modified)
Telephone
(modified)
Pain NA 0.29 0.14 NA
Distance 0.86 0.91 0.88 .04
Speed 0.82 0.92 0.90 .003
Stair-climbing 0.89 0.94 0.86 .02
WIQ, Walking Impairment Questionnaire; NA, data not available.
*Feldt statistic compares the Cronbach  of original, telephone-administered vs modified, self-administered WIQ.
Table V. Reliability: reproducibility across method of administration
WIQ subscales
Self-administered,
modified (mean  SD)
Telephone-administered,
original (mean  SD) P
Pain (n  58) 58.6  22.1 37.1  25.3 .0001
Distance (n  53) 25.4  20.1 23.0  21.4 .33
Speed (n  51) 32.7  22.3 30.0  21.6 .17
Stair-climbing (n  46) 47.4  24.1 39.7  28.9 .04
Table VI. Reliability: Intrapatient variability
WIQ subscales
Time 1
(mean  SD)
Time 2
(mean  SD) Difference P
Pearson
r* ICC
Pain (n  57) 45.6  28.2 49.7  22.3 4.8 .26 0.22 0.21
Distance (n  52) 23.5  19.5 23.8  19.5 0.3 .86 0.82 0.82
Speed (n  50) 32.4  22.0 31.2  21.8 1.2 .55 0.80 0.81
Stair-climbing (n  45) 44.9  26.5 42.4  27.1 2.5 .50 0.58 0.58
WIQ, Walking Impairment Questionnaire; ICC, intraclass correlation coefficient.
*All P values .0001 except for pain subscale.
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EQ-5D correlation with the WIQ was small to moderate (r
 0.11-0.41), with speed having the highest correlation.
Correlations between the WIQ subscales and the PAD
Symptom Scale total score were moderate (r  0.35 to
0.57), with the pain subscale most strongly correlated
with PAD symptoms. The PAD Symptom Scale had small
to moderate correlations with the SF-36, ranging from
0.26 to 0.57, and with the EQ-5D (r  0.43). As
with the WIQ, the bodily pain subscale on the SF-36 was
the most strongly correlated with the PAD Symptom Scale.
Each item of the PAD Symptom Scale was correlated
with the WIQ pain subscale items and WIQ subscales
(Table VIII, online only). The items of “cramping in calf
when walking” and “cramping in buttock when walking”
were significantly correlated with the single items from the
WIQ pain subscale asking about “pain in the calves” and
“pain in the buttocks” (r 0.73 and r 0.85, respectively;
P .001). The remaining PAD symptoms (eg, limping, leg
swelling) had small to moderate correlation (r  0.00 to
0.45) with WIQ pain items and other subscales. The
PAD item intercorrelations were also small to moderate (r
 0.03-0.59). The Cronbach  for the PAD Symptom
subscale was 0.73.
DISCUSSION
The modified WIQ demonstrates good internal consis-
tency reliability, reproducibility, and validity in both the
self-administered and telephone-administered formats for
the distance and speed subscales. This is particularly impor-
tant because these two subscales have traditionally been
used as the primary efficacy variables of the WIQ.4,7 The
modified WIQ appears to have better internal consistency
reliability than the original WIQ, on the basis of the Cron-
bach . These results suggest that themodifiedWIQ can be
used reliably and efficiently in clinical trials as either a
self-administered or telephone-administered question-
naire. The importance of this finding is that the WIQ can
now be much more easily used in large, multicenter clinical
trials comparing the effectiveness of treatments for claudi-
cation.
The purpose of this study was to evaluate themethod of
administration of the WIQ. To accomplish this, the WIQ
was modified for self-administration. This modification did
not affect the reliability or validity of the WIQ; however, it
may have affected the reproducibility of the stair-climbing
subscale, because significant differences were noted be-
tween self-administered modified WIQ and original WIQ
stair-climbing subscale scores. This difference is likely at-
tributable to the response option allowing “Don’t do for
other reasons,” and possibly to the availability of stairs, as
many respondents were not in areas where stair climbing
was an everyday occurrence (23% of participants reported
“Don’t do for other reasons” for all three stair climbing–
related items). Given these results, along with small sample
size, further study is needed for the stair climbing subscale
of the modified WIQ to establish the reliability and validity
of this subscale.
The response option “Don’t do for other reasons” was
added to counter missing responses from participants who
did not perform activities for reasons other than walking
impairment. Many older adults do not climb stairs because
they live in homes or facilities without stairs. During the
cognitive debriefing interviews for the modified WIQ, par-
ticipants stated that they understood the response option
and used it for activities that were not performed for
reasons other than walking impairment. For example, one
participant noted that she did not walk five blocks because
of asthma symptoms, not claudication pain. Use of this
option allows the patient score to not be penalized because
of non–walking impairment issues and provides an applica-
ble response rather than leaving the item response box
unchecked.
The pain subscale’s lack of consistency and reproduc-
ibility is not surprising, because the two items in this
subscale assess different areas of pain (calf vs buttock pain)
that are not the only locations of PAD-related pain. While
both calf and buttock pain during walking are symptoms of
intermittent claudication, patients experience pain in vari-
ous locations, depending on the anatomic distribution of
PAD, thus explaining the low correlation between these
two symptoms (r  0.17). Of interest, examination of the
single-item correlations of the eight-item PAD Symptom
Scale reveals that few PAD symptoms are highly correlated
with other PAD symptoms. The PAD Symptom Scale items
Table VII. Test-retest reliability
WIQ subscales Time 1 (Mean  SD) Time 2 (Mean  SD) Difference P Pearson r* ICC
Self-administered WIQ
Pain (n  26) 57.2  24.5 64.4  20.5 7.2 .04 0.72 0.68
Distance (n  26) 29.6  20.4 33.9  23.4 4.2 .20 0.73 0.72
Speed (n  26) 41.32  27.0 41.25  25.0 0.07 .98 0.83 0.83
Stair-climbing (n  24) 58.0  21.3 57.5  25.2 0.52 .89 0.70 0.70
Telephone-administered WIQ
Pain (n  24) 64.6  18.3 65.1  20.8 0.52 .83 0.82 0.82
Distance (n  20) 22.3  20.0 17.3  19.5 5.0 .09 0.80 0.78
Speed (n  20) 36.9  24.2 32.2  26.1 4.7 .25 0.75 0.74
Stair-climbing (n  14) 32.4  25.6 31.5  26.1 0.89 .80 0.87 0.88
WIQ, Walking Impairment Questionnaire; ICC, intraclass correlation coefficient.
*All P values .001.
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of pain in the calf, buttock, or both were highly correlated
with the pain in calf and buttock items in the modified
WIQ, indicating that assessment of pain can be reproduc-
ible; however, the experience and location of pain likely
vary among patients with PAD. Treat-Jacobson et al22
found that, although pain was the most frequently identi-
fied symptom of PAD in a series of qualitative interviews,
pain had the “greatest range of severity among partici-
pants.” Thus, assessment of pain in patients with PADmust
specify individual symptoms of PAD.
Increasing the pain subscale to two items was essential
for self-administration of the WIQ, to allow patients the
opportunity to differentiate perceived pain (calf vs but-
tock); however, this change made the scale inconsistent
with the original WIQ. While the pain subscale was not
reproducible or reliable in this analysis, it should be noted
that this subscale has not been typically used as an efficacy
variable in clinical studies. In clinical trials, the purpose of
the WIQ has been to assess walking impairment. If relief of
pain or symptoms is a desired outcome, then a symptom-
specific measure, such as the PAD Symptom Scale, which
demonstrated adequate internal consistency reliability and
construct validity, should be used. A potential use for WIQ
pain subscale data would be as a covariate in analyses to
possibly account for unexplained variance noted in the
other subscales, ie, distance, speed, and stair-climbing.
The finding of no differences in any of the outcome
measures (HRQL, walking impairment, symptoms) ac-
cording to ABI group was not surprising, because ABI and
walking impairment have characteristically not correlated
or have shown weak correlation, especially in smaller
groups of patients.4,23
Given the previous responsiveness and validity of a
telephone-administered original WIQ in clinical trials,9 an
in-person administered original WIQ was not included in
this study. While lack of an in-person administered original
WIQ is a limitation, it was outweighed by concerns of
patient learning effects and follow-up visit difficulty. This
study used a convenience sample of patients with PAD and
thus is limited in a diverse patient population. Our study
sample consisted primarily of well-educated white men.
Further validation of the modified WIQ in more diverse
patient populations is needed.
Method of administration did not appear to have an
effect on reliability or validity of the distance, speed, and
stair-climbing subscales of theWIQ; the distance and speed
subscales were highly reproducible. These findings suggest
that the modified WIQ subscales of distance, speed, and
stair-climbing, which have traditionally been used as effi-
cacy variables, are reliable, valid, and reproducible. Our
findings support administration of the WIQ, whether in
person, by telephone interview, or by self-administration.
This flexibility in method of administration is critical for
large, multicenter clinical trials comparing the effectiveness
of treatments for intermittent claudication.
We thank the patients who participated in this study;
Christine Thompson for statistical programming; and
Nancy Murrah at Emory University, and Amy Thomas and
Susan Smith at the University of Colorado Health Sciences
Center for assistance in patient recruitment and data col-
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Table II, online only. Demographic and clinical characteristics
Characteristics
Group 1 (N  30) Group 2 (N  30)
n % n %
Age (y) (man  SD) 67.5 9.7 66.8 10.3
PAD severity (% ABI 0.06) 15 50 12 40
Male gender 25 83.3 22 73.3
Duration of PAD symptoms (y) (mean  SD) 5.7  5.6 (N  29) 8.0  7.9
History of smoking 25 83.3 26 86.7
Comorbid condition
Angina 4 13.3 2 6.7
Arthritis 11 36.7 10 33.3
COPD 2 6.7 4 13.3
Diabetes 6 20.0 7 23.3
CAD 13 43.3 9 30.0
Myocardial infarction 4 13.3 9 30.0
Hypertension 23 76.7 24 80.0
Domestic situation
Living alone 7 23.3 12 40.0
Living with partner or spouse 21 70.0 18 60.0
Other 2 6.7 0
Race/ethnicity
African American 4 13.3 3 10.0
White 23 76.7 27 90.0
Other 2 6.7 0
Education
Elementary/primary school 0 3 10.0
Secondary/high school 18 60.0 10 33.3
College degree 8 26.7 11 36.7
Postgraduate degree 4 13.3 6 20.0
Employment status
Employed full-time 4 13.3 7 23.3
Employed part-time 4 13.3 2 6.7
Homemaker 1 3.3 0
Unemployed 0 1 3.3
Retired 17 56.7 16 53.3
Disabled 4 13.3 4 13.3
All P values  .05 between groups.
PAD, Peripheral arterial disease; ABI, ankle-brachial index; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease.
Table VIII, online only. PAD Symptom Scale correlations (N  60)
Modified WIQ
Original
WIQ Calf
cramp
when
walking
Buttocks
cramps
with
walking
Leg
swelling
Nonhealing
sores or
ulcers Limping
Nighttime
leg pain
Foot or toe
pain at
rest
Sum
pain
Calf
pain
Buttocks
pain Pain
Modified WIQ
calf pain
0.70†
Modified WIQ
buttocks pain
0.82† 0.17†
Original WIQ
pain
0.41‡ 0.49*† 0.18‡
Calf cramp
when walking
0.54*† 0.73* 0.17† 0.38*†
Buttocks cramp
when walking
0.71*† 0.16 0.85† 0.14† 0.29*
Leg swelling 0.01‡ 0.11† 0.10‡ 0.17‡ 0.08† 0.20†
Nonhealing
sores or ulcers
0.02† 0.20 0.18† 0.04† 0.04 0.39* 0.03†
Limping 0.37† 0.29* 0.28† 0.36*† 0.22 0.32* 0.19† 0.19
Nighttime leg
pain
0.34*† 0.17 0.33*† 0.00† 0.19 0.34* 0.36*† 0.10 0.42*
Foot or toe pain
at rest
0.21† 0.03 0.31† 0.03† 0.12 0.20 0.17† 0.06 0.22 0.34*
Foot or toe pain
when walking
0.34*† 0.17 0.33*† 0.25† 0.17 0.39* 0.23† 0.19 0.59* 0.41* 0.46*
*P  .05.
†N  59.
‡N  58.
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